Compounds researched for effects on muscle protein synthesis, growth-hormone/IGF-1 signaling, and soft-tissue (muscle, tendon, ligament) healing. Evidence ranges from peer-reviewed GH-secretagogue clinical/preclinical research to compounds studied mainly in animal or cell models.
Most of the literature behind this goal comes from animal and cell-culture models rather than human trials — BPC-157's tendon and gut-healing research, for instance, is almost entirely rodent-based. The GH-secretagogue compounds (ipamorelin, CJC-1295) have somewhat more clinical grounding since they work through a well-studied hormonal axis. IGF-1 LR3 in particular is worth reading closely — its published literature is mostly about the molecule as a lab reagent, not as a human therapeutic.
For educational and research purposes only. Nothing here is medical advice; these compounds are not approved for human consumption outside prescription use.
"TB-500" is a trade name for thymosin beta-4, which regulates actin polymerization and cell migration relevant to tissue repair. PubMed indexes this compound under its scientific name — the literal term "TB-500" alone returns far fewer results, so this count uses the scientific name.
Synthetic fragment of a gastric protective protein; preclinical (mostly rodent) studies show promoted angiogenesis and accelerated healing of muscle, tendon, and ligament injury.
Selective ghrelin-receptor agonist that stimulates pulsatile GH release with minimal cortisol/prolactin side effects, supporting recovery and body-composition changes.
Same GHRH-analog mechanism as in the weight-loss goal; elevated GH/IGF-1 signaling is the proposed driver of any muscle-protein-synthesis effect.
A modified, long-half-life IGF-1 analog that activates the IGF-1 receptor to drive anabolic signaling. This specific analog has almost no dedicated clinical literature — it's used mainly as a lab reagent, not a studied human therapeutic. (Native IGF-1 biology broadly is much better studied, but that reflects the natural hormone, not this analog.)
Study counts are PubMed search-result totals checked on September 24, 2026 and will change as new literature is indexed — the linked search always reflects the current live count. Vendor counts come from the products VialCheck currently tracks. This is a research index, not an endorsement of any compound, vendor, or use.